238 related articles for article (PubMed ID: 38605072)
21.
Hallaq T; Al-Hiari Y; Kasabri V; AlBashiti R; AlAlawi S; Telfah A
Anticancer Agents Med Chem; 2022; 22(19):3304-3321. PubMed ID: 35570520
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
[TBL] [Abstract][Full Text] [Related]
23. Iodoquinazoline-derived VEGFR-2 and EGFR
Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
[TBL] [Abstract][Full Text] [Related]
24. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
[TBL] [Abstract][Full Text] [Related]
25. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
27. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
31. Pyrrolizine-5-carboxamides: Exploring the impact of various substituents on anti-inflammatory and anticancer activities.
Gouda AM; Abdelazeem AH; Abdalla AN; Ahmed M
Acta Pharm; 2018 Sep; 68(3):251-273. PubMed ID: 31259695
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.
El-Mawgoud HKA; Fouda AM; El-Nassag MAA; Elhenawy AA; Alshahrani MY; El-Agrody AM
Chem Biol Interact; 2022 Mar; 355():109838. PubMed ID: 35123995
[TBL] [Abstract][Full Text] [Related]
33. Quinoline-based thiazolidinone derivatives as potent cytotoxic and apoptosis-inducing agents through EGFR inhibition.
Nafie MS; Kishk SM; Mahgoub S; Amer AM
Chem Biol Drug Des; 2022 Apr; 99(4):547-560. PubMed ID: 34873844
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
37. Development of Novel Class of Phenylpyrazolo[3,4-
Aljohani AKB; El Zaloa WAZ; Alswah M; Seleem MA; Elsebaei MM; Bayoumi AH; El-Morsy AM; Almaghrabi M; Awaji AA; Hammad A; Alsulaimany M; Ahmed HEA
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834474
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
40. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]